Bridging the treatment gap in infant medulloblastoma: Molecularly informed outcomes of a globally feasible regimen.

BACKGROUND Infant medulloblastoma represents an enormous challenge in neuro-oncology, due to their simultaneous high-risk of recurrence and high risk of severe neurodevelopmental sequelae with craniospinal irradiation. Currently infant medulloblastoma are treated with intensified protocols, either comprising intraventricular methotrexate or autologous transplant, both of which carry significant morbidity and are not feasible in the majority of the world. We sought to evaluate the molecular predictors of outcome in a cohort of infants homogeneously treated with induction chemotherapy, focal radiation and maintenance chemotherapy. METHODS A retrospective analysis of twenty-nine young children treated with a craniospinal irradiation sparing strategy from Hospital Garrahan in Buenos Aires were profiled using Illumina HumanMethylationEPIC arrays, and correlated with survival. RESULTS Twenty-nine children (range 0.3 - 4.6 years) were identified, comprising 17 SHH, 10 Group 3/4 and 2 non-medulloblastomas. Progression-free survival (PFS) across the entire cohort was 0.704 (95% CI 0.551-0.899). t-SNE analysis revealed three predominant groups, SHHβ, SHHγ and Group3. Survival by subtype was highly prognostic with SHHγ having an excellent 5-year PFS of 100% (95% CI 0.633-1) and SHHβ having a PFS of 0.56 (95% CI 0.42-1). Group 3 had a PFS of 0.50 (95% CI 0.25-1). Assessment of neurocognitive outcome was performed in 11 patients, the majority of survivors fell within the low average to mild intellectual disability, with a median IQ of 73.5. CONCLUSIONS We report a globally feasible and effective strategy avoiding craniospinal radiation in the treatment of infant medulloblastoma, including a robust molecular correlation along with neurocognitive outcomes.

[1]  F. Gilles,et al.  Excellent Outcome of Young Children with Nodular Desmoplastic Medulloblastoma Treated on "Head Start" III: A Multi-Institutional, Prospective Clinical Trial. , 2020, Neuro-oncology.

[2]  W. Whitehead,et al.  Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Souweidane,et al.  Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Derek W. Yecies,et al.  Molecular correlates of cerebellar mutism syndrome in medulloblastoma. , 2019, Neuro-oncology.

[5]  C. Hawkins,et al.  Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost , 2019, Cancer.

[6]  V. Ramaswamy,et al.  Clinical and pre-clinical utility of genomics in medulloblastoma , 2018, Expert review of neurotherapeutics.

[7]  M. Remke,et al.  Infant medulloblastoma — learning new lessons from old strata , 2018, Nature Reviews Clinical Oncology.

[8]  Martin Sill,et al.  Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.

[9]  B. Morland,et al.  Sodium Thiosulfate for Protection from Cisplatin‐Induced Hearing Loss , 2018, The New England journal of medicine.

[10]  David T. W. Jones,et al.  Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. , 2018, The Lancet. Oncology.

[11]  David T. W. Jones,et al.  Molecular characterization of medulloblastomas with extensive nodularity (MBEN) , 2018, Acta Neuropathologica.

[12]  M. Chintagumpala,et al.  Attention, processing speed, and executive functioning in pediatric brain tumor survivors treated with proton beam radiation therapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  K. Walsh,et al.  Intellectual Outcome in Molecular Subgroups of Medulloblastoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Elizabeth M. Wells,et al.  Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High‐Dose Chemotherapy , 2016, Pediatric blood & cancer.

[15]  A. V. von Bueren,et al.  Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. , 2015, European journal of cancer.

[16]  Douglas C. Miller,et al.  Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. , 2015, Pediatric neurology.

[17]  Michael D. Taylor,et al.  Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Volker Hovestadt,et al.  Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort , 2014, Acta Neuropathologica.

[19]  H. Christiansen,et al.  Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies. , 2014, International journal of radiation oncology, biology, physics.

[20]  Toshihiro Kumabe,et al.  Cytogenetic prognostication within medulloblastoma subgroups. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  David T. W. Jones,et al.  Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.

[22]  Volker Hovestadt,et al.  Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.

[23]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[24]  Douglas C. Miller,et al.  Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[26]  T. Pietsch,et al.  Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. , 2011, Neuro-oncology.

[27]  D. Figarella-Branger,et al.  Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Grill,et al.  Medulloblastoma in young children , 2010, Pediatric blood & cancer.

[29]  C. Hawkins,et al.  Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma , 2009, Current oncology.

[30]  D. Frappaz,et al.  High‐dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy , 2007, Cancer.

[31]  R. Mulhern,et al.  Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. , 2005, International journal of radiation oncology, biology, physics.

[32]  Douglas C. Miller,et al.  Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Mulhern,et al.  Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Frappaz,et al.  Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. , 2005, The Lancet. Oncology.

[35]  T. Pietsch,et al.  Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. , 2005, The New England journal of medicine.

[36]  P. Duffner Long-Term Effects of Radiation Therapy on Cognitive and Endocrine Function in Children With Leukemia and Brain Tumors , 2004, The neurologist.

[37]  W. Reddick,et al.  Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. , 2003, Neuropsychology.

[38]  A. Kiltie,et al.  Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. , 1997, Medical and pediatric oncology.

[39]  M E Cohen,et al.  Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. , 1993, The New England journal of medicine.